Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 5
Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL
Panelists discuss how they assess patients for resistance to first-line BTK inhibitor therapy in chronic lymphocytic leukemia, emphasizing the importance of clinical evaluation, laboratory testing, and genetic analysis in determining the presence and mechanisms of resistance to guide subsequent treatment decisions.
Video content above is prompted by the following:
- How do you assess patients for resistance to first-line BTK inhibitor therapy, and what role does testing play in this evaluation?
Related Content:
